Akimitsu Yamada1, Kazutaka Narui2, Sadatoshi Sugae3, Daisuke Shimizu4, Kazuaki Takabe5, Yasushi Ichikawa6, Takashi Ishikawa7, Itaru Endo3. 1. Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan. Electronic address: yakimitsu@gmail.com. 2. Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan. 3. Department of Gastroenterological Surgery, Yokohama City University, Yokohama, Kanagawa, Japan. 4. Department of Breast Surgery, Yokohama City Minato Red Cross Hospital, Yokohama, Kanagawa, Japan. 5. Breast Surgery, Roswell Park Cancer Institute, Buffalo, New York. 6. Department of Oncology, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan. 7. Department of Breast Disease, Tokyo Medical University Hospital, Tokyo, Japan.
Abstract
BACKGROUND: The standard of care for elderly women with breast cancer remains controversial. The aim of this study was to clarify the management of elderly breast cancer patients who undergo surgery. MATERIALS AND METHODS: This retrospective single-center cohort study included 2276 breast cancer patients who underwent surgery between 1993 and 2014. The patients were divided into three groups according to age: ≤64 y (young), 65-74 y (older), and ≥75 y (elderly). RESULTS: The elderly had more advanced stage disease at diagnosis (stage III and IV, 16.2%, 17.5%, and 22.1% for the young, older, and elderly groups, respectively). The elderly were more likely to undergo mastectomy (43.3%, 41.4%, and 50.7%, respectively), omit axillary operation (0.6%, 1.1%, and 9.3%, respectively), and skip radiotherapy after breast-conserving surgery (93.1%, 86.8%, and 29.1%, respectively). Endocrine therapy was widely used in all the groups (94.4%, 93.8%, and 90.1%, respectively), but frequency of chemotherapy was lower in the elderly regardless of hormone receptor (HR) status (40.8%, 25.5%, and 9.3% in HR(+), 87.2%, 75.3%, and 39.5% in HR(-), respectively). Although the locoregional recurrence rate was higher in the elderly (4.2%, 3.4%, and 7.0% at 5 y, respectively; P = 0.028), there were no differences among groups in distant metastasis-free survival or breast cancer-specific survival. CONCLUSIONS: Although elderly patients had more advanced stages of cancer and received less treatment, there were no differences in survival. Omission of axillary dissection, radiation, and chemotherapy after operation may be an option for breast cancer patients aged ≥75 y.
BACKGROUND: The standard of care for elderly women with breast cancer remains controversial. The aim of this study was to clarify the management of elderly breast cancerpatients who undergo surgery. MATERIALS AND METHODS: This retrospective single-center cohort study included 2276 breast cancerpatients who underwent surgery between 1993 and 2014. The patients were divided into three groups according to age: ≤64 y (young), 65-74 y (older), and ≥75 y (elderly). RESULTS: The elderly had more advanced stage disease at diagnosis (stage III and IV, 16.2%, 17.5%, and 22.1% for the young, older, and elderly groups, respectively). The elderly were more likely to undergo mastectomy (43.3%, 41.4%, and 50.7%, respectively), omit axillary operation (0.6%, 1.1%, and 9.3%, respectively), and skip radiotherapy after breast-conserving surgery (93.1%, 86.8%, and 29.1%, respectively). Endocrine therapy was widely used in all the groups (94.4%, 93.8%, and 90.1%, respectively), but frequency of chemotherapy was lower in the elderly regardless of hormone receptor (HR) status (40.8%, 25.5%, and 9.3% in HR(+), 87.2%, 75.3%, and 39.5% in HR(-), respectively). Although the locoregional recurrence rate was higher in the elderly (4.2%, 3.4%, and 7.0% at 5 y, respectively; P = 0.028), there were no differences among groups in distant metastasis-free survival or breast cancer-specific survival. CONCLUSIONS: Although elderly patients had more advanced stages of cancer and received less treatment, there were no differences in survival. Omission of axillary dissection, radiation, and chemotherapy after operation may be an option for breast cancerpatients aged ≥75 y.
Authors: Robert Königsberg; Georg Pfeiler; Tatjana Klement; Nicole Hammerschmid; Andreas Brunner; Robert Zeillinger; Christian Singer; Christian Dittrich Journal: Eur J Cancer Date: 2012-05-28 Impact factor: 9.162
Authors: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer Journal: JAMA Date: 2006-04-12 Impact factor: 56.272
Authors: Benjamin D Smith; Cary P Gross; Grace L Smith; Deron H Galusha; Justin E Bekelman; Bruce G Haffty Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: W J Louwman; J C M Vulto; R H A Verhoeven; G A P Nieuwenhuijzen; J W W Coebergh; A C Voogd Journal: Eur J Cancer Date: 2007-09-17 Impact factor: 9.162
Authors: Roberto Gennari; Giuseppe Curigliano; Nicole Rotmensz; Chris Robertson; Marco Colleoni; Stefano Zurrida; Franco Nolè; Filippo de Braud; Laura Orlando; Maria Cristina Leonardi; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Giuseppe Renne; Saverio Cinieri; Riccardo A Audisio; Alberto Luini; Roberto Orecchia; Giuseppe Viale; Aron Goldhirsch Journal: Cancer Date: 2004-09-15 Impact factor: 6.860
Authors: K Hancke; M D Denkinger; J König; C Kurzeder; A Wöckel; D Herr; M Blettner; R Kreienberg Journal: Ann Oncol Date: 2009-10-13 Impact factor: 32.976
Authors: Stanley P L Leong; Zhen-Zhou Shen; Tse-Jia Liu; Gaurav Agarwal; Tomoo Tajima; Nam-Sun Paik; Kerstin Sandelin; Anna Derossis; Hiram Cody; William D Foulkes Journal: World J Surg Date: 2010-10 Impact factor: 3.352
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Nam P Nguyen; Ulf Karlsson; Eromosele Oboite; Julio Alvarenga; Juan Godinez; Alice Zamagni; Micaela Motta; Satya Bose; Vincent Vinh-Hung Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241